Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) #Summit…
Tag: Therapeutics
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment
The biotech world is buzzing with excitement as Soleno Therapeutics (SLNO) has just received FDA approval…
CRISPR Therapeutics Set To Reach Previous Heights
CRISPR Therapeutics Set To Reach Previous Heights #CRISPR #Therapeutics #Set #Reach #Previous #Heights
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript
Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript #Atossa #Therapeutics #ATOS #Earnings #Call #Transcript
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts
Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts #Verve #Therapeutics #HeFH…
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 #ADC #Therapeutics…
Monte Rosa Therapeutics: Exercise Extreme Caution
Monte Rosa Therapeutics: Exercise Extreme Caution #Monte #Rosa #Therapeutics #Exercise #Extreme #Caution
Aquestive Therapeutics: Not For Me, But Attractive
Aquestive Therapeutics: Not For Me, But Attractive #Aquestive #Therapeutics #Attractive
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules#TransCode #Therapeutics #Announces #Registered #Direct…
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial…
ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in…
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before…
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in…
United Therapeutics director sells $1.55 million in stock
United Therapeutics director sells $1.55 million in stock#United #Therapeutics #director #sells #million #stock
Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript
Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company…
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock#Akebia #Therapeutics #Announces #Pricing #Public #Offering #Common…
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company…
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics#ONGOING…
ROSEN, A TOP RANKED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
ROSEN, A TOP RANKED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important…
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL)
This article was written by Follow Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with…
Akero Therapeutics CEO sells shares worth $78,001
Akero Therapeutics CEO sells shares worth $78,001#Akero #Therapeutics #CEO #sells #shares #worth
Akebia Therapeutics Inc (AKBA): Navigating Revenue Declines and Unlocking Growth Potential
In a market where growth is the holy grail, Akebia Therapeutics Inc (NASDAQ: AKBA) has been…